Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Progenitor Cell Based Market

ID: MRFR/LS/37381-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Progenitor Cell-Based Market Research Report: Size, Share, Trend Analysis By Applications (Cell Transplantation, Tissue Engineering, Regenerative Medicine, Drug Discovery, Gene Therapy), By Types (Hematopoietic Progenitor Cells, Mesenchymal Progenitor Cells, Neuronal Progenitor Cells, Endothelial Progenitor Cells), By Source (Bone Marrow, Cord Blood, Adipose Tissue, Peripheral Blood), By End Use (Hospitals, Research Laboratories, Pharmaceutical Companies, Academic Institutions) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Progenitor Cell Based Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Cell Transplantation
  50.     4.1.2 Tissue Engineering
  51.     4.1.3 Regenerative Medicine
  52.     4.1.4 Drug Discovery
  53.     4.1.5 Gene Therapy
  54.   4.2 Healthcare, BY Type (USD Billion)
  55.     4.2.1 Hematopoietic Progenitor Cells
  56.     4.2.2 Mesenchymal Progenitor Cells
  57.     4.2.3 Neuronal Progenitor Cells
  58.     4.2.4 Endothelial Progenitor Cells
  59.   4.3 Healthcare, BY Source (USD Billion)
  60.     4.3.1 Bone Marrow
  61.     4.3.2 Cord Blood
  62.     4.3.3 Adipose Tissue
  63.     4.3.4 Peripheral Blood
  64.   4.4 Healthcare, BY End-Use (USD Billion)
  65.     4.4.1 Hospitals
  66.     4.4.2 Research Laboratories
  67.     4.4.3 Pharmaceutical Companies
  68.     4.4.4 Academic Institutions
  69.   4.5 Healthcare, BY Region (USD Billion)
  70.     4.5.1 North America
  71.       4.5.1.1 US
  72.       4.5.1.2 Canada
  73.     4.5.2 Europe
  74.       4.5.2.1 Germany
  75.       4.5.2.2 UK
  76.       4.5.2.3 France
  77.       4.5.2.4 Russia
  78.       4.5.2.5 Italy
  79.       4.5.2.6 Spain
  80.       4.5.2.7 Rest of Europe
  81.     4.5.3 APAC
  82.       4.5.3.1 China
  83.       4.5.3.2 India
  84.       4.5.3.3 Japan
  85.       4.5.3.4 South Korea
  86.       4.5.3.5 Malaysia
  87.       4.5.3.6 Thailand
  88.       4.5.3.7 Indonesia
  89.       4.5.3.8 Rest of APAC
  90.     4.5.4 South America
  91.       4.5.4.1 Brazil
  92.       4.5.4.2 Mexico
  93.       4.5.4.3 Argentina
  94.       4.5.4.4 Rest of South America
  95.     4.5.5 MEA
  96.       4.5.5.1 GCC Countries
  97.       4.5.5.2 South Africa
  98.       4.5.5.3 Rest of MEA
  99. 5 SECTION V: COMPETITIVE ANALYSIS
  100.   5.1 Competitive Landscape
  101.     5.1.1 Overview
  102.     5.1.2 Competitive Analysis
  103.     5.1.3 Market share Analysis
  104.     5.1.4 Major Growth Strategy in the Healthcare
  105.     5.1.5 Competitive Benchmarking
  106.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  107.     5.1.7 Key developments and growth strategies
  108.       5.1.7.1 New Product Launch/Service Deployment
  109.       5.1.7.2 Merger & Acquisitions
  110.       5.1.7.3 Joint Ventures
  111.     5.1.8 Major Players Financial Matrix
  112.       5.1.8.1 Sales and Operating Income
  113.       5.1.8.2 Major Players R&D Expenditure. 2023
  114.   5.2 Company Profiles
  115.     5.2.1 Mesoblast (AU)
  116.       5.2.1.1 Financial Overview
  117.       5.2.1.2 Products Offered
  118.       5.2.1.3 Key Developments
  119.       5.2.1.4 SWOT Analysis
  120.       5.2.1.5 Key Strategies
  121.     5.2.2 Athersys (US)
  122.       5.2.2.1 Financial Overview
  123.       5.2.2.2 Products Offered
  124.       5.2.2.3 Key Developments
  125.       5.2.2.4 SWOT Analysis
  126.       5.2.2.5 Key Strategies
  127.     5.2.3 Cynata Therapeutics (AU)
  128.       5.2.3.1 Financial Overview
  129.       5.2.3.2 Products Offered
  130.       5.2.3.3 Key Developments
  131.       5.2.3.4 SWOT Analysis
  132.       5.2.3.5 Key Strategies
  133.     5.2.4 Regen BioPharma (US)
  134.       5.2.4.1 Financial Overview
  135.       5.2.4.2 Products Offered
  136.       5.2.4.3 Key Developments
  137.       5.2.4.4 SWOT Analysis
  138.       5.2.4.5 Key Strategies
  139.     5.2.5 Pluristem Therapeutics (IL)
  140.       5.2.5.1 Financial Overview
  141.       5.2.5.2 Products Offered
  142.       5.2.5.3 Key Developments
  143.       5.2.5.4 SWOT Analysis
  144.       5.2.5.5 Key Strategies
  145.     5.2.6 Stemcell Technologies (CA)
  146.       5.2.6.1 Financial Overview
  147.       5.2.6.2 Products Offered
  148.       5.2.6.3 Key Developments
  149.       5.2.6.4 SWOT Analysis
  150.       5.2.6.5 Key Strategies
  151.     5.2.7 Tissue Regeneration (US)
  152.       5.2.7.1 Financial Overview
  153.       5.2.7.2 Products Offered
  154.       5.2.7.3 Key Developments
  155.       5.2.7.4 SWOT Analysis
  156.       5.2.7.5 Key Strategies
  157.     5.2.8 Cellular Biomedicine Group (CN)
  158.       5.2.8.1 Financial Overview
  159.       5.2.8.2 Products Offered
  160.       5.2.8.3 Key Developments
  161.       5.2.8.4 SWOT Analysis
  162.       5.2.8.5 Key Strategies
  163.   5.3 Appendix
  164.     5.3.1 References
  165.     5.3.2 Related Reports
  166. 6 LIST OF FIGURES
  167.   6.1 MARKET SYNOPSIS
  168.   6.2 NORTH AMERICA MARKET ANALYSIS
  169.   6.3 US MARKET ANALYSIS BY APPLICATION
  170.   6.4 US MARKET ANALYSIS BY TYPE
  171.   6.5 US MARKET ANALYSIS BY SOURCE
  172.   6.6 US MARKET ANALYSIS BY END-USE
  173.   6.7 CANADA MARKET ANALYSIS BY APPLICATION
  174.   6.8 CANADA MARKET ANALYSIS BY TYPE
  175.   6.9 CANADA MARKET ANALYSIS BY SOURCE
  176.   6.10 CANADA MARKET ANALYSIS BY END-USE
  177.   6.11 EUROPE MARKET ANALYSIS
  178.   6.12 GERMANY MARKET ANALYSIS BY APPLICATION
  179.   6.13 GERMANY MARKET ANALYSIS BY TYPE
  180.   6.14 GERMANY MARKET ANALYSIS BY SOURCE
  181.   6.15 GERMANY MARKET ANALYSIS BY END-USE
  182.   6.16 UK MARKET ANALYSIS BY APPLICATION
  183.   6.17 UK MARKET ANALYSIS BY TYPE
  184.   6.18 UK MARKET ANALYSIS BY SOURCE
  185.   6.19 UK MARKET ANALYSIS BY END-USE
  186.   6.20 FRANCE MARKET ANALYSIS BY APPLICATION
  187.   6.21 FRANCE MARKET ANALYSIS BY TYPE
  188.   6.22 FRANCE MARKET ANALYSIS BY SOURCE
  189.   6.23 FRANCE MARKET ANALYSIS BY END-USE
  190.   6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
  191.   6.25 RUSSIA MARKET ANALYSIS BY TYPE
  192.   6.26 RUSSIA MARKET ANALYSIS BY SOURCE
  193.   6.27 RUSSIA MARKET ANALYSIS BY END-USE
  194.   6.28 ITALY MARKET ANALYSIS BY APPLICATION
  195.   6.29 ITALY MARKET ANALYSIS BY TYPE
  196.   6.30 ITALY MARKET ANALYSIS BY SOURCE
  197.   6.31 ITALY MARKET ANALYSIS BY END-USE
  198.   6.32 SPAIN MARKET ANALYSIS BY APPLICATION
  199.   6.33 SPAIN MARKET ANALYSIS BY TYPE
  200.   6.34 SPAIN MARKET ANALYSIS BY SOURCE
  201.   6.35 SPAIN MARKET ANALYSIS BY END-USE
  202.   6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  203.   6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE
  204.   6.38 REST OF EUROPE MARKET ANALYSIS BY SOURCE
  205.   6.39 REST OF EUROPE MARKET ANALYSIS BY END-USE
  206.   6.40 APAC MARKET ANALYSIS
  207.   6.41 CHINA MARKET ANALYSIS BY APPLICATION
  208.   6.42 CHINA MARKET ANALYSIS BY TYPE
  209.   6.43 CHINA MARKET ANALYSIS BY SOURCE
  210.   6.44 CHINA MARKET ANALYSIS BY END-USE
  211.   6.45 INDIA MARKET ANALYSIS BY APPLICATION
  212.   6.46 INDIA MARKET ANALYSIS BY TYPE
  213.   6.47 INDIA MARKET ANALYSIS BY SOURCE
  214.   6.48 INDIA MARKET ANALYSIS BY END-USE
  215.   6.49 JAPAN MARKET ANALYSIS BY APPLICATION
  216.   6.50 JAPAN MARKET ANALYSIS BY TYPE
  217.   6.51 JAPAN MARKET ANALYSIS BY SOURCE
  218.   6.52 JAPAN MARKET ANALYSIS BY END-USE
  219.   6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  220.   6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE
  221.   6.55 SOUTH KOREA MARKET ANALYSIS BY SOURCE
  222.   6.56 SOUTH KOREA MARKET ANALYSIS BY END-USE
  223.   6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
  224.   6.58 MALAYSIA MARKET ANALYSIS BY TYPE
  225.   6.59 MALAYSIA MARKET ANALYSIS BY SOURCE
  226.   6.60 MALAYSIA MARKET ANALYSIS BY END-USE
  227.   6.61 THAILAND MARKET ANALYSIS BY APPLICATION
  228.   6.62 THAILAND MARKET ANALYSIS BY TYPE
  229.   6.63 THAILAND MARKET ANALYSIS BY SOURCE
  230.   6.64 THAILAND MARKET ANALYSIS BY END-USE
  231.   6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
  232.   6.66 INDONESIA MARKET ANALYSIS BY TYPE
  233.   6.67 INDONESIA MARKET ANALYSIS BY SOURCE
  234.   6.68 INDONESIA MARKET ANALYSIS BY END-USE
  235.   6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
  236.   6.70 REST OF APAC MARKET ANALYSIS BY TYPE
  237.   6.71 REST OF APAC MARKET ANALYSIS BY SOURCE
  238.   6.72 REST OF APAC MARKET ANALYSIS BY END-USE
  239.   6.73 SOUTH AMERICA MARKET ANALYSIS
  240.   6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
  241.   6.75 BRAZIL MARKET ANALYSIS BY TYPE
  242.   6.76 BRAZIL MARKET ANALYSIS BY SOURCE
  243.   6.77 BRAZIL MARKET ANALYSIS BY END-USE
  244.   6.78 MEXICO MARKET ANALYSIS BY APPLICATION
  245.   6.79 MEXICO MARKET ANALYSIS BY TYPE
  246.   6.80 MEXICO MARKET ANALYSIS BY SOURCE
  247.   6.81 MEXICO MARKET ANALYSIS BY END-USE
  248.   6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
  249.   6.83 ARGENTINA MARKET ANALYSIS BY TYPE
  250.   6.84 ARGENTINA MARKET ANALYSIS BY SOURCE
  251.   6.85 ARGENTINA MARKET ANALYSIS BY END-USE
  252.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  253.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  254.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOURCE
  255.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE
  256.   6.90 MEA MARKET ANALYSIS
  257.   6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  258.   6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  259.   6.93 GCC COUNTRIES MARKET ANALYSIS BY SOURCE
  260.   6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USE
  261.   6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  262.   6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  263.   6.97 SOUTH AFRICA MARKET ANALYSIS BY SOURCE
  264.   6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USE
  265.   6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
  266.   6.100 REST OF MEA MARKET ANALYSIS BY TYPE
  267.   6.101 REST OF MEA MARKET ANALYSIS BY SOURCE
  268.   6.102 REST OF MEA MARKET ANALYSIS BY END-USE
  269.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  270.   6.104 RESEARCH PROCESS OF MRFR
  271.   6.105 DRO ANALYSIS OF HEALTHCARE
  272.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  273.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  274.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  275.   6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  276.   6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  277.   6.111 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  278.   6.112 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
  279.   6.113 HEALTHCARE, BY SOURCE, 2024 (% SHARE)
  280.   6.114 HEALTHCARE, BY SOURCE, 2024 TO 2035 (USD Billion)
  281.   6.115 HEALTHCARE, BY END-USE, 2024 (% SHARE)
  282.   6.116 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion)
  283.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  284. 7 LIST OF TABLES
  285.   7.1 LIST OF ASSUMPTIONS
  286.     7.1.1
  287.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  288.     7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  289.     7.2.2 BY TYPE, 2025-2035 (USD Billion)
  290.     7.2.3 BY SOURCE, 2025-2035 (USD Billion)
  291.     7.2.4 BY END-USE, 2025-2035 (USD Billion)
  292.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  293.     7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  294.     7.3.2 BY TYPE, 2025-2035 (USD Billion)
  295.     7.3.3 BY SOURCE, 2025-2035 (USD Billion)
  296.     7.3.4 BY END-USE, 2025-2035 (USD Billion)
  297.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  298.     7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  299.     7.4.2 BY TYPE, 2025-2035 (USD Billion)
  300.     7.4.3 BY SOURCE, 2025-2035 (USD Billion)
  301.     7.4.4 BY END-USE, 2025-2035 (USD Billion)
  302.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  303.     7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  304.     7.5.2 BY TYPE, 2025-2035 (USD Billion)
  305.     7.5.3 BY SOURCE, 2025-2035 (USD Billion)
  306.     7.5.4 BY END-USE, 2025-2035 (USD Billion)
  307.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  308.     7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  309.     7.6.2 BY TYPE, 2025-2035 (USD Billion)
  310.     7.6.3 BY SOURCE, 2025-2035 (USD Billion)
  311.     7.6.4 BY END-USE, 2025-2035 (USD Billion)
  312.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  313.     7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  314.     7.7.2 BY TYPE, 2025-2035 (USD Billion)
  315.     7.7.3 BY SOURCE, 2025-2035 (USD Billion)
  316.     7.7.4 BY END-USE, 2025-2035 (USD Billion)
  317.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  318.     7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  319.     7.8.2 BY TYPE, 2025-2035 (USD Billion)
  320.     7.8.3 BY SOURCE, 2025-2035 (USD Billion)
  321.     7.8.4 BY END-USE, 2025-2035 (USD Billion)
  322.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  323.     7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  324.     7.9.2 BY TYPE, 2025-2035 (USD Billion)
  325.     7.9.3 BY SOURCE, 2025-2035 (USD Billion)
  326.     7.9.4 BY END-USE, 2025-2035 (USD Billion)
  327.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  328.     7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  329.     7.10.2 BY TYPE, 2025-2035 (USD Billion)
  330.     7.10.3 BY SOURCE, 2025-2035 (USD Billion)
  331.     7.10.4 BY END-USE, 2025-2035 (USD Billion)
  332.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  333.     7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  334.     7.11.2 BY TYPE, 2025-2035 (USD Billion)
  335.     7.11.3 BY SOURCE, 2025-2035 (USD Billion)
  336.     7.11.4 BY END-USE, 2025-2035 (USD Billion)
  337.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  338.     7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  339.     7.12.2 BY TYPE, 2025-2035 (USD Billion)
  340.     7.12.3 BY SOURCE, 2025-2035 (USD Billion)
  341.     7.12.4 BY END-USE, 2025-2035 (USD Billion)
  342.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  343.     7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  344.     7.13.2 BY TYPE, 2025-2035 (USD Billion)
  345.     7.13.3 BY SOURCE, 2025-2035 (USD Billion)
  346.     7.13.4 BY END-USE, 2025-2035 (USD Billion)
  347.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  348.     7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  349.     7.14.2 BY TYPE, 2025-2035 (USD Billion)
  350.     7.14.3 BY SOURCE, 2025-2035 (USD Billion)
  351.     7.14.4 BY END-USE, 2025-2035 (USD Billion)
  352.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  353.     7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  354.     7.15.2 BY TYPE, 2025-2035 (USD Billion)
  355.     7.15.3 BY SOURCE, 2025-2035 (USD Billion)
  356.     7.15.4 BY END-USE, 2025-2035 (USD Billion)
  357.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  358.     7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  359.     7.16.2 BY TYPE, 2025-2035 (USD Billion)
  360.     7.16.3 BY SOURCE, 2025-2035 (USD Billion)
  361.     7.16.4 BY END-USE, 2025-2035 (USD Billion)
  362.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  363.     7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  364.     7.17.2 BY TYPE, 2025-2035 (USD Billion)
  365.     7.17.3 BY SOURCE, 2025-2035 (USD Billion)
  366.     7.17.4 BY END-USE, 2025-2035 (USD Billion)
  367.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  368.     7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  369.     7.18.2 BY TYPE, 2025-2035 (USD Billion)
  370.     7.18.3 BY SOURCE, 2025-2035 (USD Billion)
  371.     7.18.4 BY END-USE, 2025-2035 (USD Billion)
  372.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  373.     7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  374.     7.19.2 BY TYPE, 2025-2035 (USD Billion)
  375.     7.19.3 BY SOURCE, 2025-2035 (USD Billion)
  376.     7.19.4 BY END-USE, 2025-2035 (USD Billion)
  377.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  378.     7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  379.     7.20.2 BY TYPE, 2025-2035 (USD Billion)
  380.     7.20.3 BY SOURCE, 2025-2035 (USD Billion)
  381.     7.20.4 BY END-USE, 2025-2035 (USD Billion)
  382.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  383.     7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  384.     7.21.2 BY TYPE, 2025-2035 (USD Billion)
  385.     7.21.3 BY SOURCE, 2025-2035 (USD Billion)
  386.     7.21.4 BY END-USE, 2025-2035 (USD Billion)
  387.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  388.     7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  389.     7.22.2 BY TYPE, 2025-2035 (USD Billion)
  390.     7.22.3 BY SOURCE, 2025-2035 (USD Billion)
  391.     7.22.4 BY END-USE, 2025-2035 (USD Billion)
  392.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  393.     7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  394.     7.23.2 BY TYPE, 2025-2035 (USD Billion)
  395.     7.23.3 BY SOURCE, 2025-2035 (USD Billion)
  396.     7.23.4 BY END-USE, 2025-2035 (USD Billion)
  397.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  398.     7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  399.     7.24.2 BY TYPE, 2025-2035 (USD Billion)
  400.     7.24.3 BY SOURCE, 2025-2035 (USD Billion)
  401.     7.24.4 BY END-USE, 2025-2035 (USD Billion)
  402.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  403.     7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  404.     7.25.2 BY TYPE, 2025-2035 (USD Billion)
  405.     7.25.3 BY SOURCE, 2025-2035 (USD Billion)
  406.     7.25.4 BY END-USE, 2025-2035 (USD Billion)
  407.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  408.     7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  409.     7.26.2 BY TYPE, 2025-2035 (USD Billion)
  410.     7.26.3 BY SOURCE, 2025-2035 (USD Billion)
  411.     7.26.4 BY END-USE, 2025-2035 (USD Billion)
  412.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  413.     7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  414.     7.27.2 BY TYPE, 2025-2035 (USD Billion)
  415.     7.27.3 BY SOURCE, 2025-2035 (USD Billion)
  416.     7.27.4 BY END-USE, 2025-2035 (USD Billion)
  417.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  418.     7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  419.     7.28.2 BY TYPE, 2025-2035 (USD Billion)
  420.     7.28.3 BY SOURCE, 2025-2035 (USD Billion)
  421.     7.28.4 BY END-USE, 2025-2035 (USD Billion)
  422.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  423.     7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  424.     7.29.2 BY TYPE, 2025-2035 (USD Billion)
  425.     7.29.3 BY SOURCE, 2025-2035 (USD Billion)
  426.     7.29.4 BY END-USE, 2025-2035 (USD Billion)
  427.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  428.     7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  429.     7.30.2 BY TYPE, 2025-2035 (USD Billion)
  430.     7.30.3 BY SOURCE, 2025-2035 (USD Billion)
  431.     7.30.4 BY END-USE, 2025-2035 (USD Billion)
  432.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  433.     7.31.1
  434.   7.32 ACQUISITION/PARTNERSHIP
  435.     7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Cell Transplantation
  • Tissue Engineering
  • Regenerative Medicine
  • Drug Discovery
  • Gene Therapy

Healthcare By Type (USD Billion, 2025-2035)

  • Hematopoietic Progenitor Cells
  • Mesenchymal Progenitor Cells
  • Neuronal Progenitor Cells
  • Endothelial Progenitor Cells

Healthcare By Source (USD Billion, 2025-2035)

  • Bone Marrow
  • Cord Blood
  • Adipose Tissue
  • Peripheral Blood

Healthcare By End-Use (USD Billion, 2025-2035)

  • Hospitals
  • Research Laboratories
  • Pharmaceutical Companies
  • Academic Institutions

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions